COMPANY

LAPIX Therapeutics

Our antigen-agnostic t-cell engager approach is centered on developing a TIM (T-cell immunoglobulin and mucin domain) agonist and is combined with our in-depth knowledge of immunology and immune tolerance. From company website Source · Oct 12, 2026

Keywords: immunology Atopic Dermatitis Psoriasis Rheumatoid Arthritis Psoriatic Arthritis Autoimmune Diseases Multiple Sclerosis Relapsing-Remitting Multiple Sclerosis Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis LPX-TI641

Location: Cambridge, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

Jun 15, 2025 Trial start Phase 1: Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis source ↗
Dec 15, 2024 Trial start Phase 1: Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis source ↗
Oct 30, 2023 Trial start Phase 1: First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 source ↗
Mar 28, 2023 Trial start —: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06982352	Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis	Phase 1	Recruiting	Jun 15, 2025	Jan 15, 2026 (estimated)
NCT06628206	Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis	Phase 1	Recruiting	Dec 15, 2024	Dec 15, 2025 (estimated)
NCT05853835	First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641	Phase 1	Completed	Oct 30, 2023	Aug 15, 2024 (actual)
NCT05663853	An Observational Biomarker Study in Multiple Sclerosis (MS) Patients	Not listed	Completed	Mar 28, 2023	Apr 30, 2024 (actual)